Claire Schalon

Title: Claire Schalon: Innovator in Protein Kinase Inhibition

Introduction

Claire Schalon is a prominent inventor based in Gif-sur-Yvette, France. She has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target protein kinases. With a total of three patents to her name, her work focuses on addressing various human and animal diseases.

Latest Patents

One of her latest patents involves oxazole derivatives that inhibit Syk. This invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and inhibit signal transduction mediated by certain native and/or mutant protein kinases. These kinases are implicated in a variety of diseases, including cell proliferative, metabolic, autoimmune, allergic, hematological, inflammatory, and degenerative disorders. The compounds developed in this patent serve as Syk inhibitors and include a process for manufacturing these compounds. Another notable patent features benzimidazole derivatives as selective protein kinase inhibitors. These compounds selectively modulate, regulate, and inhibit signal transduction mediated by certain native and/or mutant protein kinases, particularly focusing on potent and selective native and/or mutant c-kit inhibitors.

Career Highlights

Claire Schalon is currently associated with Ab Science, a company known for its innovative approaches in biotechnology. Her work has been instrumental in advancing therapeutic options for various diseases through her patented inventions.

Collaborations

Some of her notable coworkers include Alain Moussy and Abdellah Benjahad, who contribute to the collaborative efforts in research and development within her field.

Conclusion

Claire Schalon's innovative work in the development of protein kinase inhibitors showcases her commitment to advancing medical science. Her contributions are vital in the ongoing fight against various diseases, and her patents reflect her expertise and dedication to the field.